Seratrodast (AA-2414) is the first thromboxane-A
2 (TXA
2) receptor antagonist. TXA
2, a metabolite of arachidonic acid [
A0781], promotes platelet aggregation and vessel constriction, and is released by platelets when these are activated by local tissue damage. Seratrodast, a TXA
2 receptor antagonist, reduces bronchial hyperresponsiveness in asthmatic subjects. Seratrodast undergoes cytochrome P450 (CYP) dependent primary metabolism to a major (5-methylhydroxy seratrodast) and a minor (4-hydroxy seratrodast) metabolite. (The product is for research purpose only.)